SYNB1020 / Synlogic - LARVOL DELTA

Safety, Tolerability and Pharmacodynamics of SYNB1020 (clinicaltrials.gov) - P1/2; N=23; Terminated; Sponsor: Synlogic; Completed ➔ Terminated; Interim futility analyses identified a lack of SYNB1020 efficacy.

Clinical • Trial termination • Fibrosis • Hepatitis C Virus • Hepatology • Immunology • Liver Failure

An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. (PubMed, Sci Transl Med) - "SYNB1020 was no longer detectable in feces 2 weeks after the last dose. These results support further clinical development of SYNB1020 for hyperammonemia disorders including urea cycle disorders and hepatic encephalopathy."

Journal

Safety, Tolerability and Pharmacodynamics of SYNB1020 (clinicaltrials.gov) - P1/2; N=23; Completed; Sponsor: Synlogic; Recruiting ➔ Completed; N=46 ➔ 23; Trial completion date: Dec 2019 ➔ Aug 2019

Clinical • Enrollment change • Trial completion • Trial completion date

"Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia https://t.co/5CI3EDhiW8" (@NewsFromBW)